- Report
- April 2024
- 181 Pages
Global
From €4785EUR$4,950USD£4,113GBP
- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Report
- January 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Report
- November 2023
- 190 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- February 2024
- 110 Pages
Global
From €4592EUR$4,750USD£3,947GBP
- Report
- February 2024
- 114 Pages
Global
From €4109EUR$4,250USD£3,531GBP
From €3625EUR$3,750USD£3,116GBP
- Report
- October 2023
- 496 Pages
Global
From €2417EUR$2,500USD£2,077GBP
- Report
- June 2023
- 430 Pages
Global
From €2417EUR$2,500USD£2,077GBP
- Report
- March 2024
- 200 Pages
Global
From €4012EUR$4,150USD£3,448GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4785EUR$4,950USD£4,113GBP
- Report
- January 2022
- 191 Pages
Global
From €4109EUR$4,250USD£3,531GBP
- Report
- October 2020
- 60 Pages
Global
From €955EUR$988USD£821GBP
€1909EUR$1,975USD£1,641GBP
- Report
- February 2022
- 145 Pages
Global
From €2416EUR$2,499USD£2,076GBP
- Report
- March 2023
- 164 Pages
Global
From €2417EUR$2,500USD£2,077GBP
- Report
- January 2019
- 95 Pages
Global
From €4157EUR$4,300USD£3,573GBP
- Report
- May 2021
- 41 Pages
Global
€1274EUR$1,318USD£1,095GBP
- Report
- April 2021
- 121 Pages
Global
From €10629EUR$10,995USD£9,136GBP
- Report
- November 2020
- 121 Pages
Global
From €10629EUR$10,995USD£9,136GBP
- Report
- October 2018
- 36 Pages
Global
From €6187EUR$6,400USD£5,318GBP
Pulmonary Fibrosis is a chronic lung disease characterized by the formation of scar tissue in the lungs, leading to difficulty breathing. It is a progressive and irreversible condition, and is the most common form of interstitial lung disease. Symptoms of Pulmonary Fibrosis include shortness of breath, dry cough, fatigue, and weight loss. Treatment options include oxygen therapy, pulmonary rehabilitation, and medications to reduce inflammation. In some cases, lung transplantation may be necessary.
The Pulmonary Fibrosis market is a subset of the Pulmonary Medicine market, which includes treatments and services for a variety of respiratory conditions. Companies in the Pulmonary Fibrosis market include Boehringer Ingelheim, Gilead Sciences, and Vertex Pharmaceuticals, which are all involved in the development of treatments for the disease. Other companies in the market include AstraZeneca, GlaxoSmithKline, and Novartis, which are involved in the development of medications to treat Pulmonary Fibrosis. Show Less Read more